Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer.
Price
Nancy
N
Sartor
Oliver
O
Hutson
Thomas
T
Mariani
Sara
S
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D018890:Chemoprevention; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D018120:Finasteride / Q000008:administration & dosage; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D017312:Toremifene / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D004791:Enzyme Inhibitors; D020845:Selective Estrogen Receptor Modulators; D018120:Finasteride; D017312:Toremifene; D042944:Cholestenone 5 alpha-Reductase